LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary

Rhea-AI Summary

LIXTE (Nasdaq: LIXT) named Sidney Braun CEO of its Liora Technologies Europe Ltd. subsidiary effective Feb 18, 2026. Braun has more than two decades of healthcare operational and advisory experience and helped create Liora and facilitate LIXTE’s acquisition of Liora assets in November 2025.

Liora develops the proprietary LiGHT System, an electronically controlled proton therapy platform the company says may offer advantages for treating tumors and support a future recurring revenue model for LIXTE.

Positive

• Acquisition of Liora assets closed in November 2025
• Named Sidney Braun as CEO of Liora with 20+ years' experience
• Strategic focus on commercializing the LiGHT System proton therapy
• Company signals pursuit of a recurring revenue model via Liora

Negative

• No regulatory approval or clearance for the LiGHT System disclosed
• No commercialization timeline or financial impact metrics provided

Market Reaction

+9.93% $3.32

15m delay 1 alert

+9.93% Since News

$3.32 Last Price

$3.00 $3.32 Day Range

+$2M Valuation Impact

$19M Market Cap

0.3x Rel. Volume

Following this news, LIXT has gained 9.93%, reflecting a notable positive market reaction. The stock is currently trading at $3.32. This price movement has added approximately $2M to the company's valuation.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.

Key Figures

Industry experience: more than two decades Asset acquisition date: November 2025

2 metrics

Industry experience more than two decades Sidney Braun’s operational and strategic advisory experience

Asset acquisition date November 2025 LIXTE’s acquisition of Liora’s assets from Orbit Capital, Inc.

Market Reality Check

Price: $3.02 Vol: Volume 13,610 is well bel...

low vol

$3.02 Last Close

Volume Volume 13,610 is well below 20-day average of 99,602 (relative volume 0.14). low

Technical Price $3.02 is trading below the 200-day MA at $3.50.

Peers on Argus

Peers show mixed moves: QTTB up 8.91%, BOLD up 1.77%, while PPCB down 7.99%, ALL...

1 Up

Peers show mixed moves: QTTB up 8.91%, BOLD up 1.77%, while PPCB down 7.99%, ALLR down 2.35%, AKTX down 1.21%. Momentum scanner only flags ICU up 3.31%, suggesting stock-specific rather than sector-wide drivers.

Common Catalyst One peer, QTTB, has conference-related news, but broader sector catalysts are limited.

Historical Context

5 past events · Latest: Jan 21 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 21	Health summit sponsorship	Positive	+4.0%	Sponsoring De La Soul-led Good Health Summit on Feb 19, 2026.
Jan 20	Conference participation	Neutral	-8.4%	Attending DealFlow Discovery Conference with investor meetings scheduled.
Dec 23	Trial expansion	Positive	-1.9%	Doubling enrollment in ovarian clear cell cancer trial of LB-100 combo.
Dec 18	Equity offering	Negative	-1.0%	Registered direct offering raising about $4.3M via units and warrants.
Dec 08	Strategy shift	Positive	+7.2%	Outlining oncology platform strategy including LiGHT System radiotherapy.

Pattern Detected

News on strategic initiatives and platforms has sometimes led to positive moves, while financings and conference appearances have seen mixed or negative reactions.

Recent Company History

Over the last few months, LIXTE has combined strategic repositioning with capital raises and clinical progress. On December 8, 2025, it highlighted a broader oncology platform strategy around LB-100 and the LiGHT System, which coincided with a 7.16% gain. A $4.3 million offering on December 18, 2025 saw a modest -1.01% move. Expansion of an ovarian cancer trial on December 23, 2025 and recent conference- and summit-related news produced mixed price reactions. Today’s leadership appointment at Liora fits into this ongoing platform build-out.

Market Pulse Summary

The stock is up +9.9% following this news. A strong positive reaction aligns with LIXTE’s ongoing ef...

Analysis

The stock is up +9.9% following this news. A strong positive reaction aligns with LIXTE’s ongoing effort to build an oncology platform around complementary modalities. The appointment of an experienced healthcare executive to lead Liora supports prior strategic moves involving the LiGHT System. Historical data show mixed but sometimes strong responses to platform and strategy updates. Investors have also navigated recent financings and trial expansions, factors that could influence how durable any move above $3.02 proves to be.

Key Terms

biologic drug, radiotherapy, proton therapy

3 terms

biologic drug medical

"building an infusion network for the biologic drug Remicade, which was approved"

A biologic drug is a medicine produced from living cells or biological molecules—such as proteins, antibodies or vaccines—rather than being chemically manufactured. It matters to investors because biologics require complex, costly development and specialized manufacturing, often command higher prices and enjoy strong intellectual-property protection, so they can drive large revenues but also carry unique production and regulatory risks; think of them as handcrafted, high‑value products versus mass‑produced pills.

radiotherapy medical

"development in the radiotherapy segment of cancer care to achieve positive patient"

Radiotherapy is a medical treatment that uses targeted high-energy radiation to shrink or destroy tumors and control disease, similar to using a focused beam to remove weeds without digging up the whole garden. It matters to investors because approvals, new technologies, clinical trial results, or changes in treatment guidelines can affect demand for equipment, drug combinations, and patient outcomes, which in turn influence revenue and growth prospects for healthcare companies.

proton therapy medical

"pioneering electronically controlled proton therapy systems for treating tumors"

A cancer treatment that uses a beam of charged particles (protons) to deliver radiation precisely to a tumor while limiting damage to surrounding healthy tissue; think of it as a GPS-guided beam that stops where the tumor is instead of blasting through everything. It matters to investors because proton therapy requires very expensive equipment, long-term facility investment and depends on clinical outcomes and insurance reimbursement to generate revenue, so advances in effectiveness, cost or access can materially affect providers' financial prospects.

AI-generated analysis. Not financial advice.

BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has appointed Sidney Braun as Chief Executive Officer of the Company’s Liora Technologies Europe Ltd. subsidiary (“Liora”).

A veteran of the healthcare industry, Braun brings to Liora more than two decades of operational and strategic advisory experience at companies in North America, Europe and Israel. He was instrumental in the creation of Liora and facilitated LIXTE’s acquisition of Liora’s assets in November 2025 from Orbit Capital, Inc.

Over his career, Braun played a key role in building an infusion network for the biologic drug Remicade, which was approved to treat several immune-mediated inflammatory diseases. He also created a physician network in Canada that was sold to Toronto-based AIM Health Group. Braun is multi-lingual and holds degrees in economics and business administration from Fordham University.

“The appointment of Sidney Braun as CEO of Liora is in keeping with our plan to bring Liora’s LiGHT System technology to the forefront of modern cancer treatment and eventually enable LIXTE to pursue a recurring revenue model,” said Geordan Pursglove, CEO of LIXTE. “We welcome Sidney to the LIXTE family and are confident of the contributions he will make to our organization and to advancing and scaling an important technology in cancer treatment.”

“Leadership in breakthrough medical technology is about building viable life-changing systems,” added Braun. “I step into my new role at Liora fully committed to fostering further development in the radiotherapy segment of cancer care to achieve positive patient outcomes and long-term value for LIXTE’s shareholders.”

Liora is pioneering electronically controlled proton therapy systems for treating tumors in various types of cancers. The Company’s proprietary flagship technology, LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy.

About LIXTE Biotechnology Holdings, Inc.

LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical and med-tech company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that LB-100, its lead compound and first-in-class lead clinical PP2A inhibitor, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. It is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE's novel approach is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma. Additional information can be found at www.lixte.com.

Through LIXTE’s wholly owned subsidiary, Liora Technologies Europe Ltd., the Company also is pioneering the development of electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora’s proprietary flagship technology, LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy. Additional information about Liora Technologies can be found at www.lioratechnologies.com.

Forward-Looking Statement Disclaimer

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal costs to protect and maintain the Company's intellectual property worldwide, and the Company’s ability to maintain compliance with Nasdaq’s continued listing requirements, are all forward-looking statements. These statements, also including but not limited to, pursuing a recurring revenue model through the Company’s acquired LiGHT system, are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology.

The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash resources, research results, competition from other similar businesses, and market and general economic factors.

Readers are urged to read the risk factors set forth in the Company’s filings with the United States Securities and Exchange Commission at https://www.sec.gov. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

For more information about LIXTE, contact: 

info@lixte.com
General Phone: (631) 830-7092; Investor Phone: (888) 289-5533
or
PondelWilkinson Inc. Investor Relations pwinvestor@pondel.com
Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962

FAQ

Who is Sidney Braun and what role did he take at LIXT (LIXT) on Feb 18, 2026?

Sidney Braun was appointed CEO of Liora Technologies Europe Ltd. on Feb 18, 2026. According to the company, Braun brings over two decades of operational and advisory experience and helped create Liora and facilitate LIXT’s November 2025 asset acquisition.

What did LIXT announce about the LiGHT System proton therapy technology on Feb 18, 2026?

LIXT said the LiGHT System is a proprietary, electronically controlled proton therapy platform believed to offer advantages in treating tumors. According to the company, Liora will advance this technology toward broader clinical and commercial use.

How does the Liora appointment affect LIXT’s business strategy and revenue model (LIXT)?

The appointment supports LIXT’s plan to scale Liora and pursue a recurring revenue model tied to LiGHT System deployments. According to the company, leadership aims to commercialize the technology and build ongoing revenue streams for shareholders.

When did LIXT acquire Liora’s assets and what is the significance for shareholders (LIXT)?

LIXT acquired Liora’s assets in November 2025, creating an operating subsidiary focused on proton therapy. According to the company, the acquisition establishes a platform to commercialize LiGHT System technology and pursue recurring revenue opportunities.

Did LIXT disclose regulatory approvals or a commercialization timeline for the LiGHT System (LIXT)?

No regulatory approvals or specific commercialization timelines were disclosed in the announcement. According to the company, the focus is on development and scaling, but no approval status or launch dates were provided.